Actively Recruiting
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
Led by Shenzhen Geno-Immune Medical Institute · Updated on 2026-04-24
10
Participants Needed
3
Research Sites
180 weeks
Total Duration
On this page
Sponsors
S
Shenzhen Geno-Immune Medical Institute
Lead Sponsor
Z
Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multi-CAR T cell therapy targeting different AML surface antigens in patients with relapsed or refractory acute myeloid leukemia (AML). Another goal of the study is to learn more about the function of the multi-CAR T cells and their persistency in the patients.
CONDITIONS
Official Title
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age older than 2 years
- Presence of CD33, CD38, CD56, CD123, MucI, and CLL1 markers on malignant cells confirmed by immuno-histochemical staining or flow cytometry
- Karnofsky performance status score higher than 80 and life expectancy greater than 2 months
- Adequate bone marrow, liver, and kidney function as shown by cardiac ejection fraction ≥ 50%, oxygen saturation ≥ 90%, creatinine ≤ 2.5 times upper limit of normal, AST and ALT ≤ 3 times upper limit of normal, total bilirubin ≤ 2.0 mg/dL
- Hemoglobin level ≥ 80 g/L
- No contraindications for cell separation
- Ability to understand and willingness to provide written informed consent
You will not qualify if you...
- Severe illness or medical condition preventing management according to the protocol, including uncontrolled active infection
- Active bacterial, fungal, or viral infection not controlled by adequate treatment
- Known HIV or hepatitis B virus infection
- Pregnant or nursing women
- Use of systemic glucocorticoids within one week prior to enrollment
- Previous treatment with any gene therapy products
- Patients deemed ineligible or unable to comply with the study by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510282
Actively Recruiting
2
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China, 518000
Actively Recruiting
3
Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center
Kunming, Yunnan, China, 650000
Actively Recruiting
Research Team
L
Lung-Ji Chang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here